With over 0.48 million Agios Pharmaceuticals Inc (AGIO) shares trading Friday and a closing price of $23.94 on the day, the dollar volume was approximately $11.4 million. The shares have shown a negative half year performance of -12.85% and its price on 12/22/23 gained nearly 4.68%. Currently, there are 55.04M common shares owned by the public and among those 54.80M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for AGIO have a consensus price objective of $38.33. The analysts have set the share’s price value over the next 12 months at a high of $49.00 and a low of $28.00. The average price target is 37.54% above its recent price level and an upside to the estimated low will see the stock gain 14.5% over that period. But an upside of 51.14% will see the stock hit the forecast high price target while median target price for the stock is $40.00.
Insiders at the company have transacted a total of 69 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 32 of these insider trades were purchases, accounting for 333,740 shares. Insider sales of the common stock occurred on 37 occasions, with total insider shares sold totaling 234,598 shares.
Shares of Agios Pharmaceuticals Inc (NASDAQ: AGIO) opened at $23.01, up $0.14 from a prior closing price of $22.87. However, the script later moved the day high at 24.05, up 4.68%. The company’s stock has a 5-day price change of 3.01% and -1.93% over the past three months. AGIO shares are trading -14.74% year to date (YTD), with the 12-month market performance down to -16.06% lower. It has a 12-month low price of $19.80 and touched a high of $31.56 over the same period. AGIO has an average intraday trading volume of 582.10K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 5.69%, 8.32%, and -2.13% respectively.
Institutional ownership of Agios Pharmaceuticals Inc (NASDAQ: AGIO) shares accounts for 100.39% of the company’s 55.04M shares outstanding.
It has a market capitalization of $1.34B and a beta (3y monthly) value of 0.81. The earnings-per-share (ttm) stands at -$3.95. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.44% over the week and 4.01% over the month.
Analysts forecast that Agios Pharmaceuticals Inc (AGIO) will achieve an EPS of -$1.62 for the current quarter, -$1.56 for the next quarter and -$5.02 for 2024. The lowest estimate earnings-per-share for the quarter is -$1.77 while analysts give the company a high EPS estimate of -$1.51. Comparatively, EPS for the current quarter was $0.67 a year ago. Earnings per share for the fiscal year are expected to decrease by -47.28%, and -1.48% over the next financial year. EPS should grow at an annualized rate of 39.00% over the next five years, compared to 8.92% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Agios Pharmaceuticals Inc (AGIO) as a “Strong Buy” at a consensus score of 1.75. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 3 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AGIO, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on February 03, 2023, with the firm’s price target at $41.
